BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Mar 31, 2016
Translation in Brief

Neighborhood loops

Specialized loop regions in chromosomes hold the keys to why and how some proto-oncogenes get activated to cause cancer, according to a group at the Whitehead Institute for Biomedical Research . The findings could provide new...
BioCentury | Mar 4, 2013
Company News

Diagnovus sales and marketing update

Diagnovus launched the Engauge-cancer-DLBCL gene expression assay diagnostic tool worldwide to aid in the stratification and treatment of patients with diffuse large B cell lymphoma (DLBCL). The RT-PCR assay, conducted on paraffin-embedded primary DLBCL tissue,...
BioCentury | Dec 16, 2010
Distillery Therapeutics

Indication: Cancer

...status Publication and contact information Cancer Neuroendocrine tumors LIM domain only 1 (LMO1) In vitro and genetic studies identified LMO1...
...that could help predict neuroblastoma aggressiveness. In 2,251 patients and 6,097 controls, genetic variants of LMO1...
...forms of the disease. In neuroblastoma cells with LMO1 risk alleles, small hairpin RNA targeting LMO1...
BioCentury | May 1, 2006
Tools & Techniques

Detective work

Although the heat from clinical and product blowups eventually subsides, researchers continue to try to elucidate the causes of the setbacks. Two recent academic reports shed such light, one expanding on the risks of COX-2...
BioCentury | Oct 20, 2003
Clinical News

Gamma-c gene therapy hematology data

Researchers published in Science previously reported results from a French study in 10 patients that showed uncontrolled exponential clonal proliferation of mature T cells occurred in 2 patients. Both patients' clones showed retrovirus vector integration...
BioCentury | Jun 16, 2003
Company News

National Human Genome Research Institute other research news

Researchers published in Science an analysis of 903 murine leukemia virus (MLV) integrations into the human genome showing that MLV preferentially integrates near the start of transcriptional units (p<0.0001). A study of 379 HIV-1 integration...
BioCentury | Feb 17, 2003
Clinical News

MFG-gamma c gene therapy to treat X-linked severe combined immunodeficiency regulatory update

The French health authority, Afssaps , released a report confirming that aberrant LM0-2 function is the probable cause of T cell lymphoproliferative disease observed in two patients taking part in a French gene therapy trial in...
BioCentury | Feb 13, 2003
Clinical News

France releases X-SCID report

The French health authority, Afssaps, released a report confirming that aberrant LM0-2 function is the probable cause of T cell lymphoproliferative disease observed in two patients taking part in a French gene therapy trial in...
BioCentury | Oct 7, 2002
Tools & Techniques

Gene therapy SCIDs

Last week's news that a patient in a French trial of gene therapy for the X-linked form of severe combined immune deficiency disease (XSCID) developed T cell lymphoproliferative disease renews concerns about the safety of...
Items per page:
1 - 10 of 13